Straits Times Index
3,323.38 +0.18 (+0.01%) S&P 500
5,235.48 -31.47 (-0.60%) Dow
38,111.48 -330.06 (-0.86%) Nasdaq
16,737.08 -183.50 (-1.08%) Bitcoin USD
68,480.20 +1,143.54 (+1.70%) CMC Crypto 200
1,431.57 -24.29 (-1.67%)
60 Degrees Pharmaceuticals, Inc. (SXTP)
After hours:
- GlobeNewswire
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humansThe study will be the world’s first clinical trial to evaluate tafenoquine in human babesiosis patientsEnrollment will begin after a site initiation visit in Boston on June 13, 2024Agreements are being negotiated with two other prominent university hospitals to expand recruitment in the Northea
- GlobeNewswire
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infectionsProminent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptomsPlanned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue/neurologic symptoms by PCRCDC estimates CFS affects 3.3 million Americans WASHINGT
- GlobeNewswire
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand.Gross profit increased from ($55.9 thousand) to $51.0 thousand. WASHINGTON, May 15, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024. Financial Highlights for the Quarter Ended Marc
